Table 1 Correlation of clinic-pathological features with LAD1 expression in NSCLC TMA cohort
From: circ-ANXA7 facilitates lung adenocarcinoma progression via miR-331/LAD1 axis
Variables | Clinicopathological features | LAD1 expression | ||
|---|---|---|---|---|
Low expression (n = 53) | High expression (n = 42) | p-value | ||
Age (years) | ≤ 65 | 23 (43.4%) | 23 (54.8%) | 0.371 |
> 65 | 30 (56.6%) | 19 (45.2%) | ||
Gender | Male | 35 (66.0%) | 23 (54.8%) | 0.364 |
Female | 18 (34.0%) | 19 (45.2%) | ||
Smoking history | Smokers | 38 (71.7%) | 24 (57.1%) | 0.207 |
Never smokers | 15 (28.3%) | 18 (42.9%) | ||
Histologic subtype | Squamous cell carcinoma | 17 (32.1%) | 20 (47.6%) | 0.183 |
Adenocarcinoma | 36 (67.9%) | 22 (52.4%) | ||
TNM stage | Stage I & II | 44 (83.0%) | 26 (61.9%) | 0.020 |
Stage III | 9 (16.9%) | 16 (38.0%) | ||
Tumor size (cm) | ≤ 5 | 45 (84.9%) | 25 (59.5%) | 0.001*** |
> 5 | 8 (15.1%) | 17 (40.5%) | ||
Lymph metastasis | No | 42 (79.2%) | 23 (54.8%) | 0.02* |
Yes | 11 (20.8%) | 19 (45.2%) | ||
Recurrence status | No | 41 (77.4 %) | 15 (35.7 %) | < 0.0001**** |
Yes | 12 (22.6 %) | 27 (64.3 %) | ||